Master Collaboration Agreement with Illumina
Novacyt S.A. has entered into a Master Collaboration Agreement with Illumina, a global leader in DNA sequencing, for an initial five-year term. This agreement establishes a framework for exploring future collaboration and product development opportunities in areas of mutual interest, with Novacyt contributing its complementary expertise. The company anticipates providing updates on material developments arising from this relationship.
Select text to share a quote on X · sign in to keep highlights & notes in your NCYT notes
Paris, France, and Manchester, UK - 1 September 2026 - Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces that it has entered into a Master Collaboration Agreement ("MCA" or "Agreement") with Illumina (NASDAQ: ILMN) a global leader in DNA sequencing and array-based technologies, for an initial five-year term.
The Agreement establishes a framework under which the parties may explore potential future collaboration in areas of mutual interest, subject to separate written project agreements. Novacyt will provide expertise complementary to Illumina, to allow exploration of deeper product development and commercial collaboration. Novacyt looks forward to providing updates on any material developments arising from the relationship as appropriate.
Lyn Rees, Chief Executive Officer, said: "The MCA establishes a strategic framework to facilitate knowledge sharing and training between Novacyt and Illumina and the potential to explore future collaboration, reflecting the value of Novacyt's product development capabilities."
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.